Latest news with #AbbottLaboratories
Yahoo
12 hours ago
- Business
- Yahoo
What to Expect From Abbott Laboratories' Q2 2025 Earnings Report
With a market cap of $233.8 billion, Abbott Laboratories (ABT) is a global healthcare company that discovers, develops, manufactures, and sells a diverse range of healthcare products across diagnostics, medical devices, nutritionals, and branded generics in emerging markets. Abbott has grown through strategic acquisitions, such as St. Jude Medical and Alere Inc., while streamlining its portfolio through divestitures, including its developed markets generics and vision care businesses. The North Chicago, Illinois-based company is slated to announce its fiscal Q2 2025 earnings results before the market opens on Thursday, July 17. Ahead of the event, analysts are expecting ABT to report an adjusted EPS of $1.25, up 9.7% from $1.14 in the year-ago quarter. The company has met or surpassed Wall Street's bottom-line estimates in the past four quarterly reports. In Q1 2025, Abbott exceeded the consensus adjusted EPS estimate by 1.9%. Holiday Trading, Trade Negotiations and Other Key Things to Watch this Week Alphabet's Strong Free Cash Flow Makes GOOG Stock a Value Buy Alibaba Is Restructuring Its E-Commerce Unit. How Should You Play BABA Stock Here? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For fiscal 2025, analysts expect the medical device maker to report adjusted EPS of $5.16, up 10.5% from $4.67 in fiscal 2024. Looking forward to fiscal 2026, adjusted EPS is expected to grow 9.9% year-over-year to $5.67. Shares of ABT have surged 28.4% over the past 52 weeks, outperforming both the S&P 500 Index's ($SPX) 12.6% rise and the Health Care Select Sector SPDR Fund's (XLV) 8.2% decline over the same period. Despite reporting weaker-than-expected Q1 2025 revenue of $10.4 billion, shares of Abbott Laboratories rose 2.8% on Apr. 16. The company reaffirmed its full-year 2025 profit forecast of $5.05 per share to $5.25 per share. Abbott also announced $500 million in new investments in manufacturing and R&D in Illinois and Texas, which are expected to mitigate the impact of U.S. tariffs estimated at around $300 million. Additionally, stronger-than-expected Q1 adjusted EPS of $1.09, along with ongoing global production of high-demand products like the FreeStyle Libre, boosted investor sentiment. Analysts' consensus rating on Abbott stock is bullish, with a "Strong Buy" rating overall. Among 26 analysts covering the stock, 18 recommend a "Strong Buy,' two have a "Moderate Buy" rating, and six give a "Hold" rating. This configuration is slightly more bullish than three months ago, with 17 analysts suggesting a "Strong Buy." The average analyst price target for ABT is $143.65, indicating a potential upside of just 6.9% from the current levels. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
2 days ago
- Business
- Yahoo
Abbott Laboratories (ABT) Surged Ahead of the Market in 2025 with Steady Earnings Momentum
Abbott Laboratories (NYSE:ABT) is one of the Best Dividend Stocks of 2025. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. In the first quarter of 2025, the company delivered strong earnings and outperformed a group of medical device peers, despite challenging conditions driven by tariffs. The company exceeded Wall Street expectations across its three key profitability metrics: earnings per share, adjusted gross margin, and adjusted pretax income margin. It also posted stronger-than-expected organic sales growth, excluding contributions from Covid testing. During the earnings call, CEO Robert Ford noted that the diagnostics business showed solid growth in all regions except China. He mentioned that growth outside China reached about 7% this quarter and that the company is exploring opportunities in other markets to balance out the impact from China. While acknowledging current headwinds, Ford reaffirmed that China remains a valuable and profitable market for the company. Abbott Laboratories (NYSE:ABT)'s dividend policy is also very strong, making it a reliable investment option for income investors. The company is a Dividend King, having raised its payouts for 53 consecutive years. It offers a quarterly dividend of $0.59 per share and has a dividend yield of 1.77%, as of June 26. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Got $500? 2 Healthcare Stocks to Buy and Hold Forever
Abbott Laboratories provides exposure to multiple areas of healthcare. AbbVie offers growth, income, and an attractive valuation. 10 stocks we like better than AbbVie › I don't know if we'll be riding in personal aircraft 20 years from now, like George Jetson did in the cartoon TV series. I don't know if artificial intelligence (AI) will replace millions of jobs. But there's one thing I'm quite confident about: We'll still need healthcare products and services in the future, whether we're talking about 10 or 100 years from now. The healthcare sector is an ideal place for long-term investors to focus their attention, in my view. The trick is to find the stocks of companies that have demonstrated an ability to adapt to changes over multiple decades and are well-positioned to succeed going forward. You won't need a fortune to get started investing in the healthcare sector. Got $500? Here are two healthcare stocks to buy and hold forever. Abbott Laboratories (NYSE: ABT) was founded in 1888. Today, it ranks among the world's most successful healthcare companies and has a market cap of $240 billion. You can buy two shares of Abbott for around $276 and still have plenty left from an initial $500 to buy the second stock on the list. That $276 will give you exposure to multiple healthcare areas. Abbott is a major force in the medical devices market, with products including the MitraClip mitral valve transcatheter edge-to-edge repair system and the FreeStyle Libre continuous glucose monitoring system. It's a top player in diagnostics, marketing products such as the Alinity family of diagnostic instruments. The company is a leader in the nutritional products space, with top-selling brands including Ensure, PediaSure, and Similac. Abbott also operates a highly successful established pharmaceuticals business, marketing branded generic drugs such as Synthroid for treating hypothyroidism and biosimilars targeting cancer, women's health, and more indications. This healthcare giant remains a nimble one. Abbott expects to grow its revenue in 2025 by 8% year over year at the midpoint of its guidance range. It's also continuing a long track record of innovation. For example, the company recently won the European CE Mark for the Volt PFA System for treating atrial fibrillation, and it's conducting a pivotal clinical trial for a new coronary intravascular lithotripsy system. On top of all that, Abbott is a Dividend King. The company has increased its dividend for an impressive 53 consecutive years. You might notice something similar about Abbott's and AbbVie's (NYSE: ABBV) names. That's no coincidence. Abbott spun off AbbVie as a separate business in 2013, but gave the new company a part of its name. AbbVie has eclipsed the success of its parent. The big biopharmaceutical company sports a market cap of around $328 billion. It generated sales of $56.3 billion last year, versus less than $42 billion for Abbott. And with AbbVie's share price hovering around $185, you should be able to scoop up one share in addition to your two shares of Abbott and still have some cash left over. The thing I like most about AbbVie is its resilience. In early 2023, the company lost U.S. exclusivity for its top-selling product, Humira. But AbbVie was well-prepared for this big blow. It had invested heavily in internal research and development, and made multiple acquisitions to bolster its pipeline. Today, AbbVie's product lineup includes two successors to Humira, Rinvoq and Skyrizi, that should rake in combined sales of $31 billion by 2027. That's much higher than Humira's peak annual sales of around $22 billion. Another thing I really like about AbbVie is its dividend. It inherited Abbott's streak of dividend increases and extended it. Since the 2013 spin-off, AbbVie has increased its dividend every year by a cumulative 310%. The company's forward dividend yield is a lofty 3.51%. As an added bonus, the stock is relatively cheap. AbbVie's shares trade at only 15.2 times forward earnings. With more growth on the way from Rinvoq and Skyrizi, as well as other products, the stock's valuation is even more attractive. Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Keith Speights has positions in AbbVie. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy. Got $500? 2 Healthcare Stocks to Buy and Hold Forever was originally published by The Motley Fool
Yahoo
5 days ago
- Business
- Yahoo
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration
Beta Bionics, Inc. BBNX recently entered into a strategic agreement with Abbott Laboratories ABT to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's upcoming dual glucose-ketone sensor in the United States. This integration is aimed at enhancing the iLet system's functionality, offering more comprehensive metabolic monitoring and further simplifying diabetes care for patients. The collaboration combines Beta Bionics' AI-driven insulin dosing technology with Abbott's expertise in continuous glucose monitoring, potentially expanding access to innovative AID solutions. By aligning with Abbott's next-generation sensor platform, BBNX is positioning itself to improve patient outcomes and strengthen its competitive edge in the growing diabetes tech landscape. Shares of the company closed flat at $17.89 on Friday following the announcement on June 18th. In the year-to-date period, BBNX shares have lost 24.3% compared with the industry's 12% decline. The S&P 500 increased 0.8% in the same time frame. However, this integration positions Beta Bionics to capture a larger share of the AID market by enhancing the clinical appeal and versatility of the iLet system. Leveraging Abbott's dual glucose-ketone sensor can improve outcomes for patients at risk of diabetic ketoacidosis, a key differentiator in a competitive landscape. Long-term, the partnership may drive wider adoption, support future regulatory approvals, and open doors to new reimbursement pathways, boosting revenue growth and market credibility. Meanwhile, BBNX currently has a market capitalization of $775.6 million. The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $84.91 million, which indicates 30.4% growth from the fiscal 2024 reported number. Image Source: Zacks Investment Research The iLet Bionic Pancreas by Beta Bionics is a fully automated insulin delivery system designed to simplify diabetes management through a closed-loop algorithm that requires only body weight for setup. It eliminates the need for manual insulin calculations by adjusting doses every five minutes based on real-time CGM data. It allows users to announce meal sizes instead of counting carbs. In a 13-week pivotal trial with 440 participants, the iLet reduced HbA1c by up to 0.7% in patients with elevated baseline levels and increased time-in-range by 2.6 hours per day without raising hypoglycemia risk. Real-world data further validated its safety, with users spending just 0.28% of time below 54 mg/dL, positioning the iLet as a clinically effective, user-friendly solution in the automated insulin delivery market. The iLet is currently compatible with Abbott's FreeStyle Libre 3 Plus CGM. The planned integration of Abbott's dual sensor, which tracks both glucose and ketone levels, aims to enhance patient safety by enabling early detection of diabetic ketoacidosis. This expanded partnership reinforces both companies' commitment to advancing diabetes technology, with the new integration expected to offer a more complete and streamlined solution for people with diabetes. Per a report by Data Bridge Market Research, the global automated insulin delivery devices market size was valued at $3.29 billion in 2024 and is projected to reach $7.83 billion by 2032, at a CAGR of 11.43%. The global automated insulin delivery devices market is experiencing significant growth, driven by the rising prevalence of diabetes and advancements in technology. Given the market potential, BBNX is likely to boost its business with its latest deal with Abbott. BBNX carries a Zacks Rank #3 (Hold) at present. A couple of better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS and Integer Holdings Corporation ITGR. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Beta Bionics, Inc. (BBNX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation
Abbott Laboratories (NYSE:ABT) ranks among the top stocks for an early retirement portfolio. On June 18, Oppenheimer reaffirmed its $140 price target and Outperform rating on Abbott Laboratories (NYSE:ABT), noting growing confidence in the company's Volt system and future glucose-ketone monitoring technology. Following the observation of live PFA (pulsed field ablation) case viewings of rival systems, such as Varipulse/CARTO and Farapulse/Opal, the research firm voiced increasing optimism concerning Volt. Varipulse's uptake has been 'subdued' despite price parity with Farapulse, according to Oppenheimer. Oppenheimer found two significant catalysts for Abbott Laboratories (NYSE:ABT) that might boost the company's performance in the second half of 2025. First, if Abbott leverages cost as a competitive advantage, the possible approval of Volt PMA might result in 'significant gains' in electrophysiology. The second driver is Abbott's glucose-ketone dual sensor system, which was recently revealed to be integrated with the insulin pump from Tandem Diabetes Care. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
